Janssen licenses its pan-influenza antibody to Leyden Labs
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza,…
Janssen's monoclonal antibody CR9114, for the potential treatment of influenza, has been exclusively licensed by Leyden Labs for development and commercialisation.